H.I.G. Capital News
Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Digestive Disease Week® 2016 Conference (DDW)
AUSTIN - May 20, 2016 — Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, will spotlight a multitude of study results for the ORBERA® Gastric Balloon and OverStitch™ Endoscopic Suturing System during Digestive Disease Week 2016.
“ORBERA® and OverStitch™ are examples of two technologies that round out Apollo Endosurgery’s offerings of less invasive bariatric and gastrointestinal products, which gastroenterologists and surgeons have enthusiastically embraced,” said Todd Newton, Chief Executive Officer of Apollo Endosurgery. “Apollo is pleased to present a number of study results that continue to show how ORBERA® can have a tremendous impact on patients’ weight loss journeys as well as the advancement of minimally invasive therapies with OverStitch™.”
Over 30 clinical abstracts will be presented on OverStitch™ and ORBERA® that include statistical proof points supporting methods to improve the efficiency and effectiveness of both products, as well as research into possible future indications, specific use cases, and advanced tactical implementation methods for each product.
During the conference, Digestive Disease Week will host several hands-on workshops including sessions that feature ORBERA® and OverStitch™ technologies. These sessions further Apollo’s mission to develop safe, effective and innovative solutions that have significant impact on minimally invasive bariatric and gastrointestinal therapies.
To learn more about ORBERA® and OverStitch™, please visit Apollo Endosurgery at booth #827 during the conference.
The OverStitch™ Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. This new technology enables a secure approximation of tissue endoscopically and a wide range of less invasive solutions for patients. OverStitch™ offers solutions for defects in both the upper and lower GI tract. Additionally, physicians are leveraging endoscopic suturing for a variety of advanced bariatric procedures. For more information regarding OverStitch™, go to: apolloendo.com.
ORBERA® is an incision-less, non-surgical weight loss solution designed for adult patients suffering from obesity, who are not appropriate for or considering invasive surgery, but for whom diet and exercise or pharmaceutical interventions have not worked.
In a non-surgical (endoscopic) procedure done under a mild sedative, the thin and deflated ORBERA® balloon is placed into the stomach. It is then filled with saline until it’s about the size of a grapefruit. The procedure typically takes about 20 to 30 minutes and the patient can generally go home the same day. At six months, through another non-surgical procedure done under a mild sedative, the ORBERA® balloon is deflated and then removed.
Once the balloon is in place, the patient receives an individually tailored support program through the ORBERA® Managed Weight Loss System team of experts – which may include a dietician, psychologist and exercise physiologist – to help keep them motivated, coordinate their program and help them work through weight loss barriers to meet their long-term weight loss goals. Coaching takes place over 12 months, even though the balloon is removed after six months. The program is designed to help the patient develop sustainable, healthy habits that will help keep weight off over time.
For more than 20 years, the global medical community has been using intragastric balloons from the makers of ORBERA® to help thousands of people lose weight. More than 220,000 ORBERA® balloons have been distributed worldwide in over 80 countries.
For additional information regarding ORBERA®, please visit orbera.com.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is revolutionizing the treatment of obesity and other gastrointestinal disorders by developing less invasive solutions for a whole new group of patients not seeking treatment today. Apollo is a global innovator pushing boundaries to bring new technologies and innovative products to markets in over 80 countries today. In particular, Apollo’s bariatric products fill the gap between non-surgical weight loss solutions and invasive surgeries, allowing physicians to do more for those patients who require more than drug therapy and dietary advice. For more information regarding Apollo Endosurgery, go to: apolloendo.com.
Media Contact For Apollo Endosurgery